Science and Law
21st August 2013

Latest News on Endocrine Disruptor Regulation in Europe

Technically, “disruption” of the endocrine system is a physiological response, not an adverse health outcome. Nevertheless, there has been much debate over the last five years.

Latest News on Endocrine Disruptor Regulation in Europe

Endocrine disruption is a broad term used by some regulators to refer to chemical compounds that are capable at some dose of affecting the endocrine system.

Technically, “disruption” of the endocrine system is a physiological response, not an adverse health outcome. Nevertheless, there has been much debate over the last five years.

Over the course of the last few days, there has been some activity on this regulatory pathway at the level of the European Commission and at the level of the French government, which we briefly summarize below. This fluid regulatory situation certainly has great impact on manufacturers of healthcare products and other chemicals. It is likely to have interesting and important implications for toxic tort and other complex scientific litigation involving chemical exposures.he European regulatory arena) to restrict the use of chemicals that have been shown to have activity on the endocrine system.

The following information was conveyed to us through Joseph Huggard of the Huggard Consulting Group, with their headquarters in Luxembourg.

The European Commission

The European Commission has been considering the development of wide-ranging regulation of any chemical compound that has been shown to have endocrine disruptor activity. This regulation was generally considered to have “no limits” (i.e., one molecule of a compound that was shown to have ED activity would have been banned) and would be implemented horizontally across all divisions and product types.

Under pressure from Catherine Day, the Commission (DG Envi) decided that their working proposal will not have horizontal criteria. There will be “horizontal” approaches led by the DGs in charge of each of the relevant divisions (e.g., DG Sanco for Pesticides and DG Envi for Biocides). Both proposals will have to go through an impact assessment.

It is our understanding that the final adoption of those horizontal approaches is expected to be completed by the end of 2014 (this would imply the application of temporary criteria between now and the end of 2014).

If this news turns out to be accurate, it highlights that the next year and a half will be ripe with opportunities in Europe to provide guidance and insight to companies that manufacture, market and distribute compounds and chemicals that are thought to have endocrine disruptor activity.

France

The French Authorities recently launched a public consultation on their strategy on endocrine disruptors. The consultation is open until 20th September.

Did you like this post? We are here to help! Schedule a consult with one of our experts.

Just fill out the form bellow and we will contact you with more information.

  • This field is for validation purposes and should be left unchanged.

Recent Related Articles

Dr. David Schwartz’s IADC Presentation: The Use of Genetic Testing in the Courtroom [Download Slides]
15 July 2020
Dr. David Schwartz’s IADC Presentation: The Use of Genetic Testing in the Courtroom [Download Slides]

On Wednesday July 8, 2020, Dr. David Schwartz of Innovative Science Solutions presented at the IADC 2020 Virtual Annual Meeting on a panel titled The Use of Genetic Testing in the Courtroom. A complimentary copy of the panel presentation is now available for download. Read more

The Use of Genetic Testing in the Courtroom: Dr. David Schwartz will be Presenting at the IADC 2020 Virtual Annual Meeting
02 July 2020
The Use of Genetic Testing in the Courtroom: Dr. David Schwartz will be Presenting at the IADC 2020 Virtual Annual Meeting

Dr. David Schwartz of Innovative Science Solutions will be presenting at the IADC 2020 Virtual Annual Meeting on a panel titled The Use of Genetic Testing in the Courtroom. Read more

WEBINAR ANNOUNCEMENT: What’s in Those Genes?
12 June 2020
WEBINAR ANNOUNCEMENT: What’s in Those Genes?

Genetic Evidence Concerning Causation for Mesothelioma 16 June 2020 at 2pm Eastern Daylight Time. Read more

Talc and Asbestos Defendants Should Monitor and Utilize Published Studies Linking Mesothelioma to Genomic Causes
28 April 2020
Talc and Asbestos Defendants Should Monitor and Utilize Published Studies Linking Mesothelioma to Genomic Causes

Plaintiff experts having been asserting for decades that all mesotheliomas must be linked to some asbestos exposure. Indeed, this has led to the erroneous (but widespread) view that mesothelioma is a signature disease, only caused by asbestos exposure. Read more

Let’s work together

The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us today

Contact us